298. Hereditary pancreatitis Clinical trials / Disease details
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02693093 (ClinicalTrials.gov) | February 24, 2016 | 12/2/2016 | A Dose Ranging Study Evaluating Efficacy and Safety of NI-03 | A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis | Chronic Pancreatitis | Drug: NI-03;Drug: Placebo | Kangen Pharmaceuticals, Inc | NULL | Completed | 18 Years | 85 Years | All | 264 | Phase 1/Phase 2 | United States;Russian Federation;Ukraine |